Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity
- 1 March 1990
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 31 (2), 121-127
- https://doi.org/10.1007/bf01742376
Abstract
Previously we have demonstrated that the in vitro generation of P815-specific anti-tumor cytotoxic T lymphocytes (CTL) was suppressed by splenic suppressor T cells from late tumor-bearing hosts (TBH). Suppression is not caused by in vitro growth of P815 from splenic metastases, since suppression was also seen with spleen cells from late TBH mice bearing a hypoxanthine/aminopterin/thymidine-sensitive subline (PHS-5) of P815 in the presence of HAT. Cyclophosphamide has been shown to inhibit theinduction of suppressor cells selectively in a number of immune responses, but evidence that it can inhibit active tumor-induced suppressor T cells is limited. We have found that suppressor T cells already induced by P815 in syngeneic late TBH are sensitive to low doses of cyclophosphamide (50 mg/kg) given 1 day before spleen harvest, but the in vitro CTL response of late TBH spleen cells could not be restored by pretreating the mice with cyclophosphamide, even when exogenous interleukin-2 was added to the cultures. Although 50 mg/kg cyclophosphamide did not inhibit the CTL response of spleen cells from mice immunized with P815 +Corynebacterium parvum, the same dose of cyclophosphamide eliminated the CTL response of spleen cells from early TBH. Interleukin-2 (IL-2) did not overcome this effect of cyclophosphamide, suggesting a direct effect on CTL. “Ultra-low”-dose cyclophosphamide (10 mg/kg) did not adversely effect early TBH CTL but was still able to eliminate suppressor T cell activity from late TBH. Nevertheless, late TBH CTL remained unresponsive after pretreatment of mice with ultra-low-dose cyclophosphamide, even when exogenous IL-2 was added in vitro. CTL precursor frequency analyses demonstrated that cyclophosphamide pretreatment had little or no effect on the numbers of CTL precursors from early TBH. Late TBH CTL precursor cells were not detectable in these studies, with or without suppressor T cell inhibition by cyclophosphamide pretreatment. Thus, it appears that most CTL precursor cells may be lost or irretrievably inactivated in the spleens of late TBH mice.Keywords
This publication has 33 references indexed in Scilit:
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.The Journal of Experimental Medicine, 1987
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- ADOPTIVE IMMUNIZATION AGAINST AN ESTABLISHED TUMOR WITH CYTOLYTIC VERSUS MEMORY T CELLSTransplantation, 1984
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- Recovery of the capacity for cytotoxic T cell generation in cyclophosphamide-treated mice by the addition of Lyt-1+2− helper cellsInternational Journal of Immunopharmacology, 1980
- Differential cyclophosphamide sensitivity of precursor cells in allogeneic and H-2 restricted cytotoxic responses.The Journal of Experimental Medicine, 1979
- DIFFERENTIAL CYCLOPHOSPHAMIDE SENSITIVITY OF SUPPRESSOR AND CYTOOXIC CELL PRECURSORSTransplantation, 1978
- Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytesThe Journal of Experimental Medicine, 1977
- Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.The Journal of Experimental Medicine, 1975